Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer.

Abstract:

Background:Bromodomain and extra-terminal domain inhibitors like JQ1 have proved to be promising epigenetic agents for the treatment of malignant ovarian carcinoma. However, the resistance of ovarian cancer cells to BET inhibitors has not been elucidated. In this study, we investigated the potential mechanisms underlying the resistance of ovarian cancer cell lines to the BET inhibitor JQ1. Materials and methods:We evaluated the apoptotic and proliferative response of four ovarian cancer cell lines to JQ1. The cell lines were designated as resistant (A2780 and HO-8910) and sensitive groups (SKOV-3 and HEY). Further experiments detected the different levels of JQ1-induced autophagy. Anti-tumour effect of the combination of JQ1 and autophagy inhibitors was tested both in vitro and in vivo. Results:In the JQ1-sensitive group, JQ1 effectively inhibited proliferation and apoptosis in a concentration-dependent manner. Conversely, JQ1 showed modest inhibition of proliferation and negligible apoptosis in the resistant group. We detected increased LC3-II lipidation, autophagosome formation, upregulation of Beclin-1 and ATG5, and downregulation of P62/SQSTM1 in the resistant group. Inhibition of JQ1-induced autophagy by pharmacologic inhibitors 3-MA and CQ enhanced the inhibition of proliferation and significantly increased the apoptosis in the JQ1-resistant group, which was also verified by in vivo experiments, indicating that JQ1-induced autophagy played a cytoprotective role. Inactivation of Akt (Ser473)/mTOR(Ser2448) pathway was associated with JQ1-induced autophagy in the resistant group. Overexpression of Akt1 suppressed autophagy and increased the anti-tumour effect of JQ1. Conclusion:These findings revealed that JQ1-induced pro-survival autophagy might be a potential mechanism in the resistance of ovarian cancer cells to BET inhibition by JQ1. Combination of JQ1 and autophagy inhibitors could be an effective therapeutic strategy for overcoming BET inhibitor resistance in ovarian cancer.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Luan W,Pang Y,Li R,Wei X,Jiao X,Shi J,Yu J,Mao H,Liu P

doi

10.2147/OTT.S220267

subject

Has Abstract

pub_date

2019-10-03 00:00:00

pages

8063-8074

issn

1178-6930

pii

220267

journal_volume

12

pub_type

杂志文章
  • MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib.

    abstract:Purpose:Sorafenib has revolutionized treatment of hepatocellular carcinoma (HCC), but its efficacy is limited by drug resistance. Autophagy is the process by which cellular components are transported to lysosomes for degradation, which promotes energy production and production of macromolecular precursors. Studies have...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S247655

    authors: Yang S,Wang M,Yang L,Li Y,Ma Y,Peng X,Li X,Li B,Jin H,Li H

    更新日期:2020-04-28 00:00:00

  • Identification of COX5B as a novel biomarker in high-grade glioma patients.

    abstract:Background:Malignant glioma is the second leading cause of cancer-related death worldwide, and is known to exhibit a high degree of heterogeneity in its deregulation of different oncogenic pathways. The molecular subclasses of human glioma are not well known. Thus, it is crucial to identify vital oncogenic pathways in ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S139243

    authors: Hu T,Xi J

    更新日期:2017-11-15 00:00:00

  • The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis.

    abstract:PURPOSE:We validated the use of expression sequence tags (ESTs) as an effective method of screening for DNA segments that could predict urothelial cell carcinoma and for identifying ESTs with such predictive value. PATIENTS AND METHODS:From 2004 to 2009, eleven patients were enrolled in this study: six with high-grade...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S69239

    authors: Yang PS,Hsu YC,Lin YH,Hou CP,Chen CL,Chang PL,Juang HH,Tsui KH

    更新日期:2014-09-30 00:00:00

  • MicroRNA-188-5p Promotes Epithelial-Mesenchymal Transition by Targeting ID4 Through Wnt/β‑catenin Signaling in Retinoblastoma.

    abstract:Purpose:Here, we investigated the involvement of the miR-188-5p/inhibitor of the DNA binding 4 (ID4) axis in retinoblastoma (Rb). Patients and methods:We included 35 Rb tissues and the corresponding adjacent normal tissues. RT-qPCR, Western blot, lentivirus transfection, measurement of cell migration in vitro, and chi...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S229739

    authors: Yang M,Li Y,Wei W

    更新日期:2019-11-27 00:00:00

  • lncRNA PCAT6 promotes non-small cell lung cancer cell proliferation, migration and invasion through regulating miR-330-5p.

    abstract:Background:Investigating the roles of lncRNA prostate cancer-associated transcript 6 (PCAT6) in modulating the growth and aggressiveness of non-small-cell lung carcinoma (NSCLC) cell. Method:The levels of PCAT6 in NSCLC tissues and cell lines were determined by quantitative real-time PCR assay. MTT as well as colony f...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S178597

    authors: Cui LH,Xu HR,Yang W,Yu LJ

    更新日期:2018-11-01 00:00:00

  • A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.

    abstract:BACKGROUND AND PURPOSE:Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer. However, diarrhea i...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S96830

    authors: Huo Z,Yu S,Hong S,Cao X,Xiu L,Liao Z,Li Y,Xiao H

    更新日期:2016-06-20 00:00:00

  • Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.

    abstract:PURPOSE:To evaluate whether the addition of two biological markers (MYC and BCL-2 protein overexpression) improves the stratification of high-risk patients with diffuse large B-cell lymphoma (DLBCL). METHOD:Seven risk factors were identified at diagnosis, and a maximum of 7 points were assigned to each patient. The pa...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S86093

    authors: Wang J,Zhou M,Xu JY,Chen B,Ouyang J

    更新日期:2015-09-18 00:00:00

  • A Six-Epithelial-Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer.

    abstract:Purpose:Pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) is associated with favourable outcomes of patients with triple-negative breast cancer (TNBC). However, a proportion of TNBC patients with the residual disease do not relapse and achieve long-term survival. The aim of this study was to ident...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S256818

    authors: Wei LY,Zhang XJ,Wang L,Hu LN,Zhang XD,Li L,Gao JN

    更新日期:2020-07-03 00:00:00

  • MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase.

    abstract:Introduction:Multiple myeloma (MM) remains an incurable disease, and patient survival requires a better understanding of this malignancy's molecular aspects. Heparanase (HPSE) is highly expressed in aggressive MM cells and related to tumor growth, metastasis, and bortezomib (BTZ) resistance. Thus, targeting HPSE seems ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S286751

    authors: Rodrigues-Junior DM,Pelarin MFA,Nader HB,Vettore AL,Pinhal MAS

    更新日期:2021-01-15 00:00:00

  • Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.

    abstract::Targeted radioimmunotherapy in non-Hodgkin's B-cell lymphoma (NHL) offers an efficacious therapy and minimal toxicity compared to conventional chemotherapy. Iodine 131 tositumomab ((131)I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to (131)I, a radio...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/ott.s4456

    authors: Burdick MJ,Macklis RM

    更新日期:2009-02-18 00:00:00

  • Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review.

    abstract::Background and aims: HOXD antisense growth-associated long noncoding RNA (HOXD-AS1) was reported to be upregulated in various cancers, such as gastric cancer, hepatocellular carcinoma, colorectal cancer, and glioma. Here, we conducted a meta-analysis and The Cancer Genome Atlas data review to investigate the clinicopa...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S184303

    authors: Zhang F,Chen X,Xi K,Qiu Z,Wang Y,Gui Y,Hou Y,Chen K,Zhang X

    更新日期:2018-11-05 00:00:00

  • SNHG3 Knockdown Suppresses Proliferation, Migration and Invasion, and Promotes Apoptosis in Non-Small Cell Lung Cancer Through Regulating miR-216a/ZEB1 Axis.

    abstract:Background:Tumour growth and development are dependent on many factors including long noncoding RNAs (lncRNAs). However, limited information is available on the involvement of lncRNAs in non-small cell lung cancer (NSCLC) and the molecular mechanisms have not been defined. Here, we examined the expression of small nucl...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S263637

    authors: Zhao S,Gao X,Zhong C,Li Y,Wang M,Zang S

    更新日期:2020-11-04 00:00:00

  • Drugs for solid cancer: the productivity crisis prompts a rethink.

    abstract::Despite remarkable progress in cancer-drug discovery, the delivery of novel, safe, and sustainably effective products to the clinic has stalled. Using Src as a model, we examine key steps in drug development. The preclinical evidence on the relationship between Src and solid cancer is in sharp contrast with the modest...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S45177

    authors: Rösel D,Brábek J,Veselý P,Fernandes M

    更新日期:2013-06-26 00:00:00

  • Leucine-rich glioma inactivated 3: integrative analyses support its prognostic role in glioma.

    abstract:BACKGROUND:Leucine-rich glioma inactivated 3 (LGI3) is a secreted protein member of LGI family. We previously reported that LGI3 was expressed in brain, adipose tissues and skin, where it played roles as a multifunctional cytokine. We postulated that LGI3 may be involved in cytokine network in cancers. AIM:This study ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S138912

    authors: Kwon NS,Kim DS,Yun HY

    更新日期:2017-05-24 00:00:00

  • Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.

    abstract::Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and ...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S90145

    authors: Chen D,Zhang Y,Shi F,Li M,Zhu H,Kong L,Yu J

    更新日期:2015-10-01 00:00:00

  • Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.

    abstract::In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the center of this review, is the phosphatidylinositol-3-kinase (PI3K) pathway. The PI3K pathway seems to play an...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S34641

    authors: Castillo JJ,Iyengar M,Kuritzky B,Bishop KD

    更新日期:2014-02-21 00:00:00

  • Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis.

    abstract:Background:The neutrophil-lymphocyte ratio (NLR), a biomarker for systematic inflammation, has been recently identified as a prognostic factor for various types of both solid and hematologic malignancies. Our study presented here was the first meta-analysis assessing the prognostic role of NLR in multiple myeloma (MM)....

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S153146

    authors: Mu S,Ai L,Fan F,Sun C,Hu Y

    更新日期:2018-01-23 00:00:00

  • CTHRC1 May Serve As A Prognostic Biomarker For Hepatocellular Carcinoma.

    abstract:Background:Hepatocellular carcinoma is a common malignant cancer and the second most common cause of cancer-related deaths worldwide. Collagen triple helix repeat containing 1 (CTHRC1) has been increasingly reported to be involved in tumorigenesis and/or tumor progression. However, limited data are available regarding ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S219429

    authors: Zhou H,Su L,Liu C,Li B,Li H,Xie Y,Sun D

    更新日期:2019-09-23 00:00:00

  • Prognostic value of FOXQ1 in patients with malignant solid tumors: a meta-analysis.

    abstract:BACKGROUND:Forkhead box Q1 (FOXQ1, also known as HFH1), a member of the forkhead transcription factor family, has been demonstrated to be overexpressed in multiple tumors and is thought to be an indicator of poor clinical outcomes. METHODS:A meta-analysis using qualified relevant literature was performed to evaluate t...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S130905

    authors: Cui X,Zhang J,Lv J,Yan Y,Liu X,Wang J,Lv Y,Zhang J

    更新日期:2017-03-23 00:00:00

  • Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression.

    abstract:Background:Despite the breadth of understanding the noncoding RNAs' function in molecular biology, their functional roles in hepatocellular carcinoma (HCC) is poorly understood. In this study, we investigated the effect of hepatitis C virus (HCV) core upon the expression of noncoding RNAs. Methods:The lncRNAs, mRNAs, ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S149254

    authors: Wang X,Peng J,Wang J,Li M,Wu D,Wu S,Liao J,Dou J

    更新日期:2018-03-02 00:00:00

  • Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

    abstract::Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HE...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S27733

    authors: Hamizi S,Freyer G,Bakrin N,Henin E,Mohtaram A,Le Saux O,Falandry C

    更新日期:2013-01-01 00:00:00

  • Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.

    abstract::Angiogenesis plays an essential role in the development of most solid tumors by delivering nutrients and oxygen to the tumor. Therefore, anti-angiogenic therapy, particularly anti-VEGF and anti-VEGF receptor (VEGFR) therapy, has been a popular strategy to treat cancer. However, anti-angiogenic therapy does not signifi...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S276150

    authors: Tian W,Cao C,Shu L,Wu F

    更新日期:2020-11-24 00:00:00

  • Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.

    abstract:AIM:To investigate the significance of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER3 expression on survival outcomes in Chinese gastric cancer patients. MATERIALS AND METHODS:Formalin-fixed, paraffin-embedded specimens from 121 patients who underwent gastrectomy at Sh...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S70922

    authors: Tang D,Liu CY,Shen D,Fan S,Su X,Ye P,Gavine PR,Yin X

    更新日期:2014-12-16 00:00:00

  • Association of TIMP-2-418G/C and TIMP-2-303G/A with gastric cancer: a meta-analysis.

    abstract:BACKGROUND:According to the relevant reports, TIMP-2 polymorphism might be associated with the susceptibility to gastric cancer. Owing to the inconclusive results from the published studies based on the association between TIMP-2 single nucleotide polymorphisms (SNPs) and gastric cancer susceptibility, a meta-analysis ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S114113

    authors: Yang Y,Xiong Y,Li J,Wu C,Jiang J

    更新日期:2016-11-03 00:00:00

  • Daily rhythm variations of the clock gene PER1 and cancer-related genes during various stages of carcinogenesis in a golden hamster model of buccal mucosa carcinoma.

    abstract:BACKGROUND:Recent studies have demonstrated that the clock gene PER1 regulates various tumor-related genes. Abnormal expressions and circadian rhythm alterations of PER1 are closely related to carcinogenesis. However, the dynamic circadian variations of PER1 and tumor-related genes at different stages of carcinogenesis...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S83710

    authors: Ye H,Yang K,Tan XM,Fu XJ,Li HX

    更新日期:2015-06-11 00:00:00

  • Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.

    abstract::Lung cancer is the leading cause of cancer-related mortality in both sexes, accounting for over one quarter of cancer deaths. Non-small-cell lung cancer (NSCLC) comprises 85%-90% of lung cancer diagnoses and despite advances in multimodality therapies, 5-year survival rates remain dismal with a median survival for pat...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S67262

    authors: Kanaan Z,Kloecker GH,Paintal A,Perez CA

    更新日期:2015-04-20 00:00:00

  • The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells.

    abstract:Background:Chemotherapy remains a major clinical option for the successful treatment of cancer by eliminating fast-growing populations of cancer cells. However, drug resistance causes the failure of antitumor treatment. Increasing evidence suggests that a small subpopulation of cancer cells will enter a "persister stat...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S212465

    authors: Wang L,Yang Q,Peng S,Liu X

    更新日期:2019-07-08 00:00:00

  • MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2.

    abstract:Background:Growing evidence suggests that miR-150 plays an inhibitory role in various types of cancer. However, the function and underlying mechanisms of miR-150 in triple-negative breast cancer (TNBC) remain unknown. Patients and methods:miR-150 expression was detected by qRT-PCR and ISH in TNBC tumor and adjacent no...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S161996

    authors: Tang W,Xu P,Wang H,Niu Z,Zhu D,Lin Q,Tang L,Ren L

    更新日期:2018-04-24 00:00:00

  • Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer.

    abstract:Background/aim:Urothelial bladder cancer arises from the accumulation of multiple epigenetic and genetic changes. We aimed to investigate the specificity and sensitivity of gene-specific promoter methylation of CDH1 and p14ARF genes in the early diagnosis of bladder cancer and compare those with other diagnostic tests ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S158259

    authors: Bayramov B,Gunes S,Buyukalpelli R,Aydın O,Henkel R

    更新日期:2018-07-19 00:00:00

  • Clinical treatment of advanced synchronous triple primary malignancies: comprehensive treatment based on targeted therapy.

    abstract::The prevalence of cancer remains high. With the improvement of diagnosis and treatment level and the increase of cancer survivors after treatment, multiple primary tumors are more common than before. The diagnosis and treatment of synchronous multiple primary tumors is more complicated than that of single or metachron...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S200625

    authors: Zhang Y,Ge Y,Wu X,Liu S

    更新日期:2019-04-02 00:00:00